Chelsea blindsided again on Northera plan; shares plunge
This article was originally published in Scrip
Executive Summary
Investors' confidence in Chelsea Therapeutics' ability to read the US FDA is waning, with shares of the firm tumbling as low as 52% on 3 July after the agency for the second time in recent months expressed doubt about how the company is going about providing efficacy and safety data for Northera (droxidopa) – declaring the company's latest proposal insufficient, making the drug's path to approval much more complex.